Trial Condition(s):

Hirsutism, Dermatitis, Seborrheic Alopecia, Severe Acne, Seborrhea

Study on the Prescribing Indications for combinations of cyproterone acetate and ethinylestradiol in 5 European Countries

Bayer Identifier:

17194

ClinicalTrials.gov Identifier:

NCT02494297

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study is designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers. The primary objective of the study is to characterize the prescribing behaviors for Cyproterone Acetate combined with Ethinyl Estradiol in 5 European countries (Austria, Czech Republic, France, the Netherlands, and Spain), including:

•prescription indications for Cyproterone Acetate combined with Ethinyl Estradiol
•use of Cyproterone Acetate combined with Ethinyl Estradiol in accordance with the updated label
•concomitant use of Cyproterone Acetate combined with Ethinyl Estradiol and combined hormonal contraceptives
•second line treatment with Cyproterone Acetate combined with Ethinyl Estradiol for the indication acne

Inclusion Criteria
- Women who are prescribed CPA/EE medication during the study period.
 - Women who are willing to participate in the drug utilization study
Exclusion Criteria
- Women who are not willing to sign the informed consent
 - Women with a language barrier

Trial Summary

Enrollment Goal
1408
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Diane 35 (EE/CPA, BAY86-5264)
Accepts Healthy Volunteers
No

Where to Participate

Locations
Status
LocationsStatus

Trial Design